{"prompt": "['2.1', 'OBJECTIVES', '2.1.1', 'Primary Objective', 'The primary objective for this study is to evaluate patient preference for pertuzumab and', 'trastuzumab FDC SC on the basis of the following endpoint:', 'Proportion of patients who preferred pertuzumab and trastuzumab FDC SC with', 'treatment preference assessed via Question 1 of the Patient Preference Questionnaire', '(PPQ).', '2.1.2', 'Secondary Objectives', 'Secondary objectives for this study are to evaluate:', 'Patient assessed satisfaction with pertuzumab and trastuzumab FDC SC and P+H IV', 'based on patient responses to Question 1 of the Therapy Administration Satisfaction', 'Questionnaire - subcutaneous (TASQ-SC) and TASQ - intravenous (TASQ-IV)', \"Patients' choice of pertuzumab and trastuzumab FDC SC for the Treatment Continuation\", 'Period based on the proportion of patients who select pertuzumab and trastuzumab FDC', 'SC for this study period', 'HCP perception of time/resource use and convenience with pertuzumab and', 'trastuzumab FDC SC based on HCP responses to the Healthcare Professional', 'Questionnaires (HCPQs), by individual question', 'HRQoL with pertuzumab and trastuzumab FDC SC and P+H IV based on change in', 'symptoms and function from baseline and over time as assessed by European', 'Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30', '(EORTC QLQ-C30) scores, and mean and mean changes from baseline score in', 'HRQoL by cycle as assessed by the Global Health Status / overall quality of life (QoL)', 'scale (items 29 and 30) of the EORTC QLQ-C30.', '2.1.2.1', 'Secondary Safety Objectives', 'There are two secondary safety objectives for this study. The first is to evaluate the safety', 'and tolerability of pertuzumab and trastuzumab FDC SC and P+H IV during the study', 'Treatment Cross-over Period and the entire adjuvant treatment period (Treatment Cross-', 'over Period + Treatment Continuation Period) based on the following endpoints:', 'Incidence, nature and severity of all AEs, Grade 3 AEs, serious adverse events (SAEs)', 'and cardiac AEs (including left ventricular ejection fraction [LVEF] events)', 'Incidence of premature withdrawal from study treatment', 'Targeted vital signs and physical findings', 'Targeted clinical laboratory test results', 'The second safety objective for this study is to evaluate the safety of switching from', 'pertuzumab and trastuzumab FDC SC to P+H IV and from P+H IV to pertuzumab and', 'trastuzumab FDC SC based on:', 'Incidence, nature and severity of all AEs, Grade 3 AEs, SAEs and cardiac AEs', '(including LVEF events) during the study Treatment Cross-over Period by treatment arm.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '35 / Protocol MO40628, Version 12']['For all safety endpoints, AE severity will be determined according to the National Cancer', 'Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)', '2.1.2.2', 'Secondary Efficacy Objective', 'The secondary efficacy objective for this study is to evaluate the long-term efficacy of the', 'pertuzumab and trastuzumab FDC SC and P+H IV based on the following endpoints:', 'Invasive disease-free survival, defined as the time from randomization to the first', 'occurrence of one of the following events:', '- Ipsilateral invasive breast tumour recurrence (i.e., an invasive breast cancer involving', 'the same breast parenchyma as the original primary lesion)', '-', 'Ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast', 'cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the lipsilateral', 'breast)', '- Distant recurrence (i.e., evidence of breast cancer in any anatomic site other than the', 'two above mentioned sites that has either been histologically confirmed or clinically', 'diagnosed as recurrent invasive breast cancer)', '- Contralateral invasive breast cancer', '-', 'Death attributable to any cause, including breast cancer, non-breast cancer, or', 'unknown cause (but cause of death should be specified, if possible)', 'Note: Ipsilateral or contralateral in situ disease and second primary non-breast cancers', '(including in situ carcinomas and non-melanoma skin cancers) will not be counted as', 'recurrence.', 'Invasive disease-free survival including second primary non-breast cancer, defined as', 'IDFS with second primary non-breast invasive cancer (with the exception of non-', 'melanoma skin cancers and in situ carcinoma of any site) included as an event', 'Distant disease-free survival (DDFS), defined as the time from randomization to the date', 'of distant breast cancer recurrence', 'OS, defined as the time from randomization to death from any cause.', '3.', 'STUDY DESIGN', '3.1', 'DESCRIPTION OF THE STUDY', 'This is a Phase II, randomized, multi-centre, multinational, open-label, cross-over study in', 'adult patients who have completed neoadjuvant chemotherapy with neoadjuvant Perjeta and', 'Herceptin and have undergone surgical treatment of HER2+ EBC. An overview of the study', 'design is provided in Figure 1.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '36 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}